重大事件
即時報告
8-K
2026-06-22
STAAR Surgical年度股東大會通過董事選舉及股權激勵計劃擴容390萬股
AI 繁中摘要
📄 **STAAR Surgical Company (STAA) 8-K 申報摘要**
申報日期：2026年6月22日（事件發生日期：2026年6月18日）
STAAR Surgical Company 於2026年6月18日舉行年度股東大會，並就四項提案進行表決，結果如下：
1. **選舉七名董事**（任期至2027年年度股東大會）：
所有候選人均獲通過，包括 Neal C. Bradsher、Arthur C. Butcher、Wei Jiang、Richard T. LeBuhn、Louis E. Silverman、Christopher M. Wang 及 Lilian Y. Zhou。每人均獲得約 4,000 萬至 4,100 萬股贊成票，反對票甚少，惟部分候選人錄得約 240 萬股經紀人非投票（broker non-votes）。
2. **批准股權激勵計劃第二修正案**（增加 390 萬股授權股份）：
以約 4,023 萬股贊成、97.5 萬股反對及 6.8 萬股棄權通過，另有約 240 萬股經紀人非投票。此修正案將公司普通股儲備發行量由原先數量再增加 390 萬股，用於未來股權獎勵。
3. **批准聘任 BDO USA, P.C. 為截至2027年1月1日止財政年度的獨立註冊會計師事務所**：
以約 4,343 萬股贊成、23.7 萬股反對及 1 萬股棄權通過，無經紀人非投票。
4. **諮詢性高管薪酬投票（非約束性）**：
以約 3,974 萬股贊成、145.4 萬股反對及 8.3 萬股棄權通過，另有約 240 萬股經紀人非投票。
**潛在投資者影響**：
- 股權激勵計劃擴容（+390 萬股）顯示公司繼續以股權獎勵留住及激勵員工，但可能帶來未來稀釋效應，投資者需關注每股盈利影響。
- 高管薪酬諮詢投票獲逾九成贊成（不計經紀人非投票），反映股東對現行薪酬安排基本滿意。
- 審計師續任穩定性高，減少會計風險。
整體而言，本次股東大會結果屬預期之內，未出現重大爭議事項，公司治理及激勵機制維持正常運作。
展開英文正文
8-K 0000718937false00007189372024-06-202024-06-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2026 STAAR Surgical Company (Exact Name of Registrant as Specified in Charter) Delaware 000-11634 95-3797439 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 25510 Commercentre Drive Lake Forest, California 92630 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 626-303-7902 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common STAA NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 18, 2026, STAAR Surgical Company (the “Company”) held its 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, the Company’s shareholders approved Amendment No. 2 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) to increase the number of shares of common stock reserved for issuance thereunder by 3,900,000 shares (the “Plan Amendment”). Descriptions of the Plan and the Plan Amendment can be found in “Proposal No. 2: Approval of Amendment No. 2 to Amended and Restated Omnibus Equity Incentive Plan” in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 4, 2026 (the “2026 Proxy Statement”). Such descriptions are incorporated herein by reference from the 2026 Proxy Statement and are qualified in their entirety by reference to the Plan, a copy of which is filed as Exhibit 10.1 to this current report, Amendment No. 1 to the Plan, a copy of which is filed as Exhibit 10.2 to this current report, and the Plan Amendment, a copy of which is filed as Exhibit 10.3 to this current report. Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2026 Annual Meeting, the Company’s shareholders voted upon four proposals (the “Proposals”), as described in the 2026 Proxy Statement. The final results for the votes cast with respect to the Proposals are set forth below. As of April 20, 2026, the record date for the 2026 Annual Meeting, there were 49,788,295 outstanding shares of the Company’s common stock. At the 2026 Annual Meeting, a quorum of 43,680,435 shares of the Company’s common stock were represented in person or by proxy. Proposal 1: To elect seven directors to serve for a term of office expiring at the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified: Number of Shares For Withheld Broker Non-Votes Neal C. Bradsher 40,776,719 497,602 2,406,114 Arthur C. Butcher 40,565,567 708,754 2,406,114 Wei Jiang 41,098,173 176,148 2,406,114 Richard T. LeBuhn 41,170,957 103,364 2,406,114 Louis E. Silverman 40,487,195 787,126 2,406,114 Christopher M. Wang 40,941,468 332,853 2,406,114 Lilian Y. Zhou 40,488,276 786,045 2,406,114 Proposal 2: To approve Amendment No. 2 to the Company’s Amended and Restated Omnibus Equity Incentive Plan, which increases the number of shares of Company common stock that are reserved for issuance under the plan by 3.9 million shares: Number of Shares For Against Abstain Broker Non-Votes 40,231,475 974,989 67,857 2,406,114 Proposal 3: To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending January 1, 2027: Number of Shares For Against Abstain Broker Non-Votes 43,433,234 237,151 10,050 0 Proposal 4: To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes 39,737,385 1,454,186 82,750 2,406,114 Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2024). 10.2 Amendment No. 1 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2024). 10.3* Amendment No. 2 to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). ________ * Filed herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company June 22, 2026 By: /s/ Deborah Andrews Deborah Andrews Interim Co-Chief Executive Officer and Chief Financial Officer